Prediction and Testing of Antigenic Sites of the AIDS Virus, HTLV-III Recognized by T Lymphocytes for the Development of Synthetic Vaccines

National Cancer Institute (NCI) logo

National Cancer Institute (NCI)

Status

Completed

Conditions

Healthy
HIV Infections

Study type

Observational

Funder types

NIH

Identifiers

NCT00001210
860199
86-C-0199

Details and patient eligibility

About

Subjects are healthy adult volunteers either at high risk for HIV infection or already known to be seropositive, who will donate blood for in vitro tests of T-cell function and in vitro responses to synthetic peptides corresponding to sequences from HIV proteins.

Full description

Subjects are healthy adult volunteers either at high risk for HIV infection or already known to be seropositive, who will donate blood for in vitro tests of T-cell function and in vitro responses to synthetic peptides corresponding to sequences from HIV proteins.

Sex

All

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion criteria for the at risk group will be a statement from the donor that he is an active homosexual or bisexual.

Homosexual donors must not have AIDS.

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems